论文部分内容阅读
目的:分析研讨非布司他治疗痛风伴高尿酸血症疾病的临床状况。方法:此研究中所研讨的100例患者均随机从我院2013年4月至2016年1月期间所收治的痛风伴高尿酸血症患者中挑选而出,依据随机抽签法将100例患者分为50例对照组和50例研究组,对照组接受别嘌呤醇治疗,研究组接受非布司他治疗,将两组患者治疗状况做出对比分析。结果:从两组患者肝肾功能指数对比上来看,包含Cr、BUN、AST、ALT指数,研究组和对照组之间,数据无统计学意义(P<0.05)。研究组并发症总发生6%和对照组16%之间对比,数据无统计学意义(P<0.05)。结论:临床在治疗痛风伴高尿酸血症时可考虑给予非布司他治疗,疗效突出,安全性高,存在较大应用价值。
Objective: To analyze the clinical status of febuxostat for the treatment of gout with hyperuricemia. Methods: All 100 patients studied in this study were randomly selected from patients with gout and hyperuricemia admitted from April 2013 to January 2016 in our hospital. According to the randomized drawing method, 100 patients 50 cases of control group and 50 cases of study group, the control group received allopurinol treatment, the study group received febuxostat treatment, the two groups of patients to make a comparative analysis of treatment. Results: There was no significant difference between the two groups in data of liver and kidney function index (Cr, BUN, AST, ALT index, between study group and control group) (P <0.05). There was no significant difference between the study group (6%) and the control group (6%) (P <0.05). Conclusion: The clinical treatment of gout with hyperuricemia may consider giving febuxostat treatment, with outstanding curative effect, high safety and great application value.